Literature DB >> 17640189

Clostridium difficile-associated diarrhoea.

B Elliott1, B J Chang, C L Golledge, T V Riley.   

Abstract

Clostridium difficile is an important nosocomial pathogen and the most frequently diagnosed cause of infectious hospital-acquired diarrhoea. Toxigenic strains usually produce toxin A and toxin B, which are the primary virulence factors of C. difficile. Some recently described strains produce an additional toxin, an adenosine-diphosphate ribosyltransferase known as binary toxin, the role of which in pathogenicity is unknown. There has been concern about the emergence of a hypervirulent fluoroquinolone-resistant strain of C. difficile in North America and Europe. The use of fluoroquinolone antimicrobials appears to be acting as a selective pressure in the emergence of this strain. In this review, we describe the current state of knowledge about C. difficile as a cause of diarrhoeal illness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17640189     DOI: 10.1111/j.1445-5994.2007.01403.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  37 in total

1.  Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.

Authors:  Jennifer Steele; Kevin Chen; Xingmin Sun; Yongrong Zhang; Haiying Wang; Saul Tzipori; Hanping Feng
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

Review 2.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Both, toxin A and toxin B, are important in Clostridium difficile infection.

Authors:  Sarah A Kuehne; Stephen T Cartman; Nigel P Minton
Journal:  Gut Microbes       Date:  2011-07-01

4.  Nonantimicrobial drug targets for Clostridium difficile infections.

Authors:  Charles Darkoh; Magdalena Deaton; Herbert L DuPont
Journal:  Future Microbiol       Date:  2017-07-31       Impact factor: 3.165

5.  TPL2 Is a Key Regulator of Intestinal Inflammation in Clostridium difficile Infection.

Authors:  Yuanguo Wang; Shaohui Wang; Ciaran P Kelly; Hanping Feng; Andrew Greenberg; Xingmin Sun
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

6.  Recurrent Clostridium difficile Infection in Children: Patient Risk Factors and Markers of Intestinal Inflammation.

Authors:  Maribeth R Nicholson; Jonathan D Crews; Jeffrey R Starke; Zhi-Dong Jiang; Herbert DuPont; Kathryn Edwards
Journal:  Pediatr Infect Dis J       Date:  2017-04       Impact factor: 2.129

7.  Using a Novel Lysin To Help Control Clostridium difficile Infections.

Authors:  Qiong Wang; Chad W Euler; Aurelia Delaune; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

8.  Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production.

Authors:  Sarah Underwood; Shuang Guan; Vinod Vijayasubhash; Simon D Baines; Luke Graham; Richard J Lewis; Mark H Wilcox; Keith Stephenson
Journal:  J Bacteriol       Date:  2009-09-25       Impact factor: 3.490

9.  Clostridium difficile-associated enteric disease after percutaneous endoscopic gastrostomy.

Authors:  Shiro Yokohama; Masaru Aoshima; Toshiyuki Asama; Junya Shindo; Junichi Maruyama
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

10.  Clostridium difficile toxin B-induced colonic inflammation is mediated by the FOXO3/PPM1B pathway in fetal human colon epithelial cells.

Authors:  Qingqing Xu; Ying Li; Yuejuan Zheng; Yijian Chen; Xiaogang Xu; Minggui Wang
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.